Baird analyst Jeff Johnson raised the firm’s price target on Zimmer Biomet to $155 from $149 and keeps an Outperform rating on the shares. The firm said its end markets are firming, commercial execution is improving, and now, with a new $200M cost-savings program, the path to consistent double-digit EPS growth seems to be clearing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZBH: